Mounjaro, Zepbound pour money into Eli Lilly, fueling a better-than-expected second quarter

INDIANAPOLIS (AP) — Eli Lilly blew past second-quarter expectations with the diabetes treatment Mounjaro and its weight loss counterpart Zepbound funneling more than $4 billion in sales to the drugmaker. Lilly also hiked its forecast for the year well beyond Wall Street...